

1 **Dynamics of SARS-CoV-2 exposure in Malawian blood donors: a retrospective**

2 **seroprevalence analysis between January 2020 and February 2021**

3 Mandolo J¹ϕ, Msefula J¹ϕ, Henrion MYR^{1,2}, Brown C¹, Moyo B¹, Samon A³, Moyo-Gwete T^{4,5},
4 Makhado Z^{4,5}, Ayres F^{4,5}, Motlou T^{4,5}, Mzindle N^{4,5}, Kalata N¹, Muula AS⁶, Kwatra G^{7,8,9},
5 Msamala N³, Likaka A³, Mfuno T³, Moore PL^{4,5}, Mbaya B³, French N¹⁰, Heyderman RS¹¹,
6 Swarthout TD^{1,11}¶, Jambo KC^{1,2}¶*

7

8 1. Malawi-Liverpool-Wellcome Trust Clinical Research programme, Blantyre, Malawi

9 2. Liverpool School of Tropical Medicine, Liverpool, United Kingdom

10 3. Malawi Blood Transfusion Services, Blantyre, Malawi

11 4. National Institute for Communicable Diseases of the National Health Laboratory
12 Services, South Africa

13 5. MRC Antibody Research Unit, School of Pathology, University of the Witwatersrand,
14 South Africa

15 6. Kamuzu University of Health Sciences, Blantyre, Malawi

16 7. Respiratory and Meningeal Pathogens Research Unit, South Africa

17 8. Department of Science/ National Research Foundation: Vaccine Preventable Diseases,
18 University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa.

19 9. Department of Clinical Microbiology, Christian Medical College, Vellore, India.

20 10. University of Liverpool, Liverpool, United Kingdom

21 11. NIHR Global Health Research Unit on Mucosal Pathogens, Research Department of
22 Infection, Division of Infection and Immunity, University College London, London, UK

23

24 ***Corresponding author**

25 Email: Kondwani.Jambo@lstmed.ac.uk or kjambo@mlw.mw (KCJ)

26

27 ϕ Joint first authors

28 ¶ Joint senior authors

29

30 **Main text:** 3488 words

31

32 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Running title: SARS-CoV-2 antibodies in Malawian blood donors

33 **Abstract**

34 **Background:** As at end of July 2021, the COVID-19 pandemic has been less severe in sub-
35 Saharan Africa than elsewhere. In Malawi, there have been two subsequent epidemic
36 waves. We therefore aimed to describe the dynamics of SARS-CoV-2 exposure in Malawi.

37 **Methods:** We measured the seroprevalence of anti-SARS-CoV-2 antibodies among randomly
38 selected blood donor sera in Malawi from January 2020 to February 2021. In a subset, we
39 also assessed *in vitro* neutralisation against the original variant (D614G WT) and the Beta
40 variant.

41 **Findings:** A total of 3586 samples were selected from the blood donor database, of which
42 2685 (74.9%) were male and 3132 (87.3%) were aged 20-49 years. Of the total, 469 (13.1%)
43 were seropositive. Seropositivity was highest in October 2020 (15.7%) and February 2021
44 (49.7%) reflecting the two epidemic waves. Unlike the first wave, both urban and rural areas
45 had high seropositivity by February 2021, Balaka (rural, 37.5%), Blantyre (urban, 54.8%),
46 Lilongwe (urban, 54.5%) and Mzuzu (urban, 57.5%). First wave sera showed potent *in vitro*
47 neutralisation activity against the original variant (78%[7/9]) but not the Beta variant (22%
48 [2/9]). Second wave sera potentially neutralised the Beta variant (73% [8/11]).

49 **Interpretation:** The findings confirm extensive SARS-CoV-2 exposure in Malawi over two
50 epidemic waves with likely poor cross-protection to reinfection from the first on the second
51 wave. Since prior exposure augments COVID-19 vaccine immunity, prioritising
52 administration of the first dose in high SARS-CoV-2 exposure settings could maximise the
53 benefit of the limited available vaccines in Malawi and the region.

54

55 **Word count:** 247 words

56

57

58

59

60

61

62

63

64 **Research in context**

65 **Evidence before this study**

66 We searched PubMed on August 16, 2021, with no language restrictions, for titles and
67 abstracts published between Jan 1, 2020, and August 16, 2021, using the search terms:
68 “SARS-CoV-2 seroprevalence in Africa”[Title/Abstract]) OR “SARS-CoV-2 seroprevalence in
69 blood donors” [Title/Abstract] OR “SARS-CoV-2 seroprevalence in Malawi”, and found 15
70 records. There are limited SARS-CoV-2 seroprevalence studies in sub Saharan Africa,
71 however the few that are available report high seroprevalence than can be deduced from
72 the respective national reported COVID-19 cases and deaths. Only two published SARS-CoV-
73 2 serosurveys were done on blood donors, from Kenya and Madagascar. Blood donor
74 serosurveys have been recommended by the WHO as an important tool for assessing the
75 spread of SARS-CoV-2 and estimating the burden of COVID-19 pandemic.

76

77 **Added value of this study**

78 Unlike previous SARS-CoV-2 blood donor serosurveys in African populations that were
79 conducted for a maximum period of 9 months, our study covers a full year from January
80 2020 to February 2021, capturing potential introduction of SARS-CoV-2 into Malawi as well
81 as the two epidemic waves. This study provides evidence against the speculation that SARS-
82 CoV-2 had been circulating more widely in sub-Saharan Africa before the first detected
83 cases. It also provides supporting evidence suggesting that the Beta variant was the likely
84 driver of the second wave that resulted in high SARS-CoV-2 seropositivity in January to
85 February 2021 in Malawi.

86

87 **Implications of all the available evidence**

88 Our results show extensive community transmission of SARS-CoV-2 in Malawi as reflected in
89 the blood donors serosurvey, with almost half the sample population being seropositive for
90 anti-SARS-CoV-2 antibodies by February 2021. This has implications for COVID-19
91 vaccination policy in sub-Saharan Africa (SSA), where there are limited available vaccine
92 doses. Considering that prior exposure to SARS-CoV-2 augments COVID-19 vaccine
93 immunity, strategies to maximise administration of the first vaccine dose, while waiting for
94 more vaccines to become available, could maximise the benefits of the limited available
95 vaccines in high SARS-CoV-2 exposure settings in SSA such as Malawi.

96 **Introduction**

97 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in
98 Hubei province, China as a cause of coronavirus disease 2019 (COVID-19)^{1,2}. SARS-CoV-2
99 infection presents with a range of disease manifestations, from asymptomatic infection to
100 severe acute respiratory distress and death. SARS-CoV-2 has spread globally and the World
101 Health Organisation (WHO) declared COVID-19 a global pandemic on 11th March 2020. As of
102 12th August 2021, more than 205 million people globally have been infected with more than
103 4.32 million deaths³. The pandemic has placed substantial pressures on health systems
104 delivering care for patients with COVID-19 and caused disruption of non-COVID-19 health-
105 care provision, in addition to negative effects on the global economy⁴.

106
107 The potential risk from SARS-CoV-2 to Africa was identified early in the global pandemic⁵.
108 As the epicentre of transmission moved from East Asia to West Asia, Europe and then to
109 North America, there was speculation as to the likely impact of the pandemic on the African
110 continent with its younger populations, high rates of infectious diseases including HIV,
111 poverty and undernutrition, as well as a fragile health care infrastructure^{5,6}. Evidence has
112 shown that the epidemiology of the COVID-19 pandemic in sub-Saharan Africa has been
113 different from the Americas, China and Europe³. Available seroprevalence data indicate
114 that SARS-CoV-2 has circulated more widely in African populations than can be deduced
115 from the number of reported confirmed cases, hospitalisations and deaths⁷⁻⁹. This has led
116 to speculations that SARS-CoV-2 could have circulated longer in sub-Saharan Africa than the
117 first confirmed cases, but current evidence is limited. Others have speculated that a high
118 prevalence of circulating seasonal coronaviruses could have induced some cross-reactive
119 protective immunity^{10,11}.

120
121 SARS-CoV-2 Spike and Nucleocapsid specific antibody responses in blood are detectable in
122 individuals between 5 to 21 days post symptom onset¹². Subsequently, anti-SARS-CoV-2
123 IgM antibody levels drop sharply within the initial 14 days followed by a gradual decline in
124 anti-SARS-CoV-2 IgG antibodies within the next 6 months¹³, reaching undetectable levels in
125 some individuals¹⁴. Whether these antibodies are likely to be protective against subsequent
126 infections is becoming clearer. Anti-SARS-CoV-2 Spike antibodies generated following
127 exposure to the original viral variant (D614G) exhibit reduced neutralisation potency against

128 the alpha and beta variants of SARS-CoV-2¹⁵⁻¹⁷. Conversely, antibodies generated following
129 infection with the beta variant are able to potently neutralise the original variant¹⁸⁻²⁰.

130

131 Though there were initial plans made by the Malawi government in April 2020 to implement
132 a national lockdown of social and commercial activities, these were never implemented²¹.

133 As such, unlike other countries in the region, including Kenya²², South Africa²³ and

134 Zimbabwe²⁴, there were no systematic lockdowns and limited curfew restrictions. Schools

135 were officially closed (from 23rd March 2020 to 7th September 2020) and many social

136 gathering settings (including restaurants and places of worship) voluntarily closed or had

137 significantly reduced services^{25,26}. Malawi closed its borders and airports from April 2020 to

138 September 2020, with limited essential traffic allowed in and out of the country²⁷. As of 12th

139 August 2021, 56,952 people were confirmed to have been infected by SARS-CoV-2 in

140 Malawi, resulting in 1,895 deaths and 169,632 people had been fully vaccinated³.

141

142 Due to movement restrictions instituted to curb SARS-CoV-2 transmission, conducting large

143 national population-based seroprevalence studies has been a significant challenge. This has

144 led to the use of blood donor and healthcare worker serosurveys to estimate and monitor

145 the extent of the SARS-CoV-2 pandemic in several countries^{7-9,28}. Here, we report results of

146 a national serosurvey using archived serum samples from blood transfusion donors across

147 Malawi from January 2020 through February 2021, generated using a WHO-recommended

148 anti-SARS-CoV-2 Receptor Binding Domain total antibody assay with high sensitivity and

149 specificity, supported by SARS-CoV-2 pseudovirus neutralisation assays to explore variant

150 specificity.

151

152 **Methods**

153 **Study setting and population**

154 The Malawi Blood Transfusion Service (MBTS) maintains an archive of sera from all blood

155 donations received in their Malawi facilities (average of 70,000 annually before the COVID-

156 19 pandemic). All blood donors undergo routine screening through a self-administered

157 questionnaire, one-on-one assessment and a mini-health screening by MBTS staff. Donors

158 meeting routine donor ineligibility criteria including age below 16 or above 65 years,

159 haemoglobin below 12.5g/dl, past medical history suggestive of HIV, hepatitis or syphilis,

160 past or present history of renal, cardiovascular, central nervous system and metabolic
161 disorders, are excluded from donating²⁹. All donated samples are screened for Transfusion
162 Transmissible Infections (TTI; including HIV). Sera are archived at -80°C and retained by
163 MBTS for up to 5 years for retrospective analysis purposes. MBTS blood donation services
164 include both static and mobile sites. For our analysis, we have selected samples from all four
165 defined regions within Malawi: Mzuzu is the capital of the Northern Region and the third
166 largest city, by population, in Malawi (population of 221,272). Lilongwe is Malawi's
167 capital city located in the Central Region (population of 989,318). Blantyre is the capital
168 of Malawi's Southern Region (population of 800,264). Balaka is a rural district of 438,379
169 residents, located in the Eastern Region. All population data are from the 2018 Malawi
170 Population and Housing Census³⁰.

171

172 Ethical approval for this study was obtained from the Kamuzu University of Health Sciences
173 Research Ethics Committee (P.09/20/3123). At time of donation, blood donors provide
174 consent to draw blood for transfusion and for use in studies of public health importance.
175 COVID-19 research qualifies as an activity of urgent public health importance.

176

177 **Sample selection and processing**

178 Using the MBTS sample archive database, we randomly selected (using STATA's gsample
179 command) sera collected from HIV-seronegative individuals aged 16-65 years old.
180 Parameters including sex, age, location and time were also extracted from the database for
181 analysis. For Mzuzu, Lilongwe and Blantyre, selected samples were only from static urban
182 donation sites. For Balaka, a largely rural district with smaller total donations, selected
183 samples included donations from both static and mobile sites, including semi-rural and
184 rural.

185

186 **Measurement of SARS-CoV-2 antibodies by Enzyme Linked-Immunosorbent Assay**

187 ***SARS-CoV-2 Receptor Binding Domain (RBD) Total Antibody ELISA.***

188 We used the WHO-approved WANTAI SARS-CoV-2 Ab commercial Enzyme Linked-
189 Immunosorbent Assay (ELISA) kit to detect total SARS-CoV-2 antibodies, following
190 manufacturer's instructions (Beijing Wantai Biological Pharmacy Enterprise co., Ltd, China;
191 WS-1096) as reported previously³¹. This ELISA was shown to have the best overall

192 characteristics to detect functional antibodies in different phases and severity of disease ³¹.
193 It is a two-step incubation antigen “sandwich” enzyme immunoassay kit which uses
194 polystyrene microwell strips pre-coated with recombinant SARS-CoV-2 Receptor Binding
195 Domain (RBD) antigen. The optical density (OD) of each well was read at 450nm in a
196 microplate reader (BioTek ELx808, UK) within 10 minutes of adding Stop Solution. Cut-off
197 values were calculated following manufacturer’s instructions. The ratio between a sample’s
198 absorbance and the cut-off were calculated for each sample. Specimens giving a ratio of
199 <0.9 were reported as negative for this assay, a ratio of >1.1 were reported as positive, and
200 a ratio between 0.9-1.1 were reported as borderline. Samples with borderline results were
201 retested using a confirmatory assay described below. The sensitivity and specificity of the
202 assay as independently validated are 97% [95% CI 83.3 to 99.4] and 98% [91.3 to 99.3]),
203 respectively ³². The manufacturer’s sensitivity and specificity estimates for the assay are
204 94% [90.9 to 96.8] and 100% [98.8 to 100], respectively³³.

205

206 **Confirmatory SARS-CoV-2 Spike 2 and Nucleoprotein IgG antibody ELISA.** The COVID-19 IgG
207 RUO commercial ELISA kit (Omega diagnostics, UK) kit uses 96-well microtiter plates pre-
208 coated with purified SARS-COV-2 Spike (S2) and Nucleoprotein (N) antigens to detect SARS-
209 COV-2 IgG. This was performed following manufacturer’s instructions as reported
210 previously⁷. Results were interpreted as described above for the ELISA assay, with a ratio of
211 <0.9 reported as negative, a ratio of >1.1 reported as positive, and a ratio between 0.9-1.1
212 reported as borderline.

213

214 **SARS-CoV-2 Pseudovirus Neutralisation Assay**

215 Samples were pre-screened using an in-house (NICD) spike ELISA¹⁶, and only samples
216 positive for binding antibodies were screened for neutralization. SARS-CoV-2-pseudotyped
217 lentiviruses were prepared by co-transfecting the HEK 293T cell line with either the SARS-
218 CoV-2 original spike (D614G) or the SARS-CoV-2 Beta spike (L18F, D80A, D215G, K417N,
219 E484K, N501Y, D614G, A701V, 242-244 del) plasmids in conjunction with a firefly luciferase
220 encoding pNL4 lentivirus backbone plasmid. The parental plasmids were kindly provided by
221 Drs Elise Landais and Devin Sok (The International AIDS Vaccine Initiative (IAVI), USA). For
222 the neutralization assay, heat-inactivated seropositive serum samples from blood donors
223 were incubated with the SARS- CoV-2 pseudotyped virus for 1 hour at 37°C, 5% CO₂.

224 Subsequently, 1×10^4 HEK 293T cells engineered to over-express ACE-2, kindly provided by Dr
225 Michael Farzan (Scripps Research), were added and incubated at 37°C, 5% CO₂ for 72 hours
226 upon which the luminescence of the luciferase gene was measured.

227

228 **Statistical analysis**

229 We performed statistical analyses and graphical presentation using R statistical package,
230 version 4.1.0 and GraphPad Prism v9.1.0 (GraphPad Software, LLC). The seroprevalence of
231 SARS-CoV-2 antibodies was adjusted for the independently reported assay sensitivity (97%
232 [95% CI 83.3 to 99.4]) and specificity (98% [95% CI 91.3 to 99.3]) using the bootComb
233 (v1.0.1) R package³⁴. Generalised additive models were used to estimate the
234 seroprevalence curves from Figures 1 and 2. To investigate demographic factors associated
235 with SARS-CoV-2 antibody positivity, a multivariable logistic regression model was
236 developed with sex, age group, location and time as predictors. To obtain smooth regression
237 curves, B-splines³⁵ were used to model the effect of time given the non-linear trend in
238 seroprevalence over time. Effects were considered statistically significant when the *p*-value
239 was less than 0.05.

240 **Results**

241 **Participant demographics**

242 A total of 3,586 blood donor serum samples were selected from the four regional blood
243 transfusion centres. Samples had been collected between January 2020 through February
244 2021. These included 823 from Mzuzu (Northern region), 946 from Lilongwe (Central
245 region), 830 from Balaka (Eastern region) and 987 from Blantyre (Southern region) (**Table 1**).
246 Compared with 2018 Malawi Population and Housing Census³⁰, by the nature of the
247 demographic of blood donors in Malawi, participants were more commonly male (75% in
248 our study versus 48.5% in the census) and had more persons aged 20 to 49 years (87.3%
249 versus 35.4%).

250

251 **Overall SARS-CoV-2 antibody seroprevalence**

252 Of the 3,586 samples, 456 were positive for anti-SARS-CoV-2 RBD total antibody and 17
253 were borderline. After re-running the borderline samples using the separate commercial
254 confirmatory ELISA, 13 of the 17 were positive for anti-SARS-CoV-2 S2 and N IgG antibody,

255 resulting in a total 469 anti-SARS-CoV-2 antibody positive samples (crude seroprevalence of
256 13.1% [95% CI 12.0% to 14.2%]).

257

258 As part of quality control procedures, we randomly selected 76 samples that were positive
259 on the primary SARS-CoV-2 ELISA and retested them using the second ELISA targeting S2
260 and NP IgG. Seventy-one (71) of the 76 samples were positive on the second ELISA,
261 representing a concordance of 93.4% [95% CI 85.3 to 97.8]. We also used a recently
262 published ELISA from the National Institute for Communicable Diseases (NICD, South
263 Africa)¹⁶ that targets binding antibodies against RBD of the original SARS-CoV-2 variant on a
264 subset of 36 serum samples selected from the seroprevalence peaks. The concordance
265 between the Wantai and NICD assays was 100%.

266

267 The overall (all months aggregated) seroprevalence adjusted for the reported independent
268 sensitivity and specificity estimates was 11.2% [95% CI from 5.8% to 14.9%]. In a
269 multivariable logistic regression model, seroprevalence did not vary significantly by sex ($p =$
270 0.532) or age ($p > 0.10$ for all age groups using those 10-19 years old as reference) but did
271 vary geographically, from 5.5% in Balaka (reference) to 14.6% in Blantyre ($p < 0.001$), 9.8% in
272 Lilongwe ($p < 0.001$) and 14.6% in Mzuzu ($p < 0.001$) (**Table 2**).

273

274 **Temporal trend of SARS-CoV-2 seroprevalence**

275 The first PCR-confirmed case of COVID-19 identified by Malawi's national surveillance
276 system was on 2nd April 2021, with the first peak of the national COVID-19 cases being July
277 2020 (2,813 cases) and subsequently a second peak in January 2021 (17,380 cases) (**Figure**
278 **1**). In this blood donor SARS-CoV-2 serosurvey, the first seropositive samples were observed
279 in February 2020 in Balaka (1 sample) and March 2020 in Blantyre (2 samples) (**Figure 2**,
280 **Table 3 and Supplementary Table 1**). Both unadjusted and adjusted seroprevalence
281 estimates increased with time, with two distinct waves that followed the same temporal
282 trend as the reported national COVID-19 cases (**Figure 1 and Supplementary Table 1**). When
283 aggregating serum samples from all locations, the first wave among donors was observed
284 from July to November 2020 with the peak seroprevalence in October 2020 (15.7% adjusted
285 seroprevalence), while the second wave was observed between December 2020 to February
286 2021 with peak seroprevalence in February 2021 (49.4%) (**Figure 1, Table 3 and**

287 **Supplementary Table 1**). However, there were differences in the temporal trend in
288 seroprevalence according to location (**Figure 2, Table 3 and Supplementary Table 1**). Balaka
289 had a 0% adjusted seroprevalence from January to November 2020, subsequently increasing
290 from 1.9% to 37.5% between December 2020 and February 2021. The peak adjusted
291 seroprevalence in the first wave was July 2020 in the Blantyre (15.9%), August 2020 in
292 Lilongwe (13.1%) and October 2020 in Mzuzu (24.8%). Seroprevalence bubble plots at three
293 periods in time demonstrated widespread exposure amongst blood donors across the
294 country in February 2021 compared to the earlier snapshots (**Figure 3**).

295

296 **Estimating predominant SARS-CoV-2 variants driving seroprevalence**

297 Limited evidence suggests that Malawi's second wave was driven by the Beta variant, with
298 data deposited on GISAID showing that the variant was identified in 96% (152/159) of the
299 samples sequenced from Malawi from January 2021³⁶. As it has been shown that antibodies
300 elicited by the original variant (D614G WT) are less potent against the Beta variant^{16,19}, we
301 reasoned that differential neutralisation potency by SARS-CoV-2 antibodies could be used to
302 estimate the predominance of specific variants driving seroprevalence. We therefore
303 measured neutralisation antibody responses against D614G WT and Beta variant in
304 randomly selected seropositive sera collected at the peak of the first wave (Wave 1) in June
305 to October 2020 compared to those collected in February 2021 (Wave 2). Wave 1 sera was
306 more potent against D614G WT than the Beta variant, while Wave 2 sera was relatively
307 more potent against the Beta variant than D614G WT (**Figure 4a-b**). Only 22% (2/9) of the
308 Wave 1 sera was more potent against the Beta variant than D614G WT, while 47% 8/17 of
309 the Wave 2 sera was more potent against the Beta variant than D614G WT (**Figure 4b-c**). In
310 contrast, 78% (7/9) of the Wave 1 sera was more potent against D614G WT than the Beta
311 variant, while 18% 3/17 of the Wave 2 sera was more potent against D614G WT than the
312 Beta variant (**Figure 4c**). Furthermore, 35% (6/17) of the Wave 2 sera showed no
313 neutralisation against the Beta variant or D614G WT (**Figure 4c**). Collectively, these results
314 support existing sequencing evidence that Malawi's second SARS-CoV-2 epidemic wave was
315 driven by the Beta variant.

316

317

318

319 Discussion

320 Our study provides important insights into the dynamics of the COVID-19 epidemic in both
321 urban and rural Malawi, with likely relevance to the southern Africa region. The
322 seroprevalence estimates from this blood donor serosurvey are very high compared to the
323 reported national surveillance figures for confirmed asymptomatic and symptomatic cases,
324 but they do reflect the emergence and magnitude of the first and second COVID-19
325 epidemic waves in Malawi. They also provide evidence against the speculation that SARS-
326 CoV-2 had been circulating more widely in Malawi before the first detected case in April
327 2020 or that circulation of endemic coronaviruses^{10,11} had generated cross-reactive
328 antibody responses. Data from pseudovirus neutralisation assays suggests that the second
329 wave was predominantly driven by the Beta variant, as sera from the first wave had poor
330 neutralising activity against the Beta variant of SARS-CoV-2. Collectively, our findings
331 provide further support to the emerging data that in terms of hospitalised disease and
332 death, the COVID-19 pandemic has so far been attenuated in sub-Saharan Africa, despite
333 high population exposure to SARS-CoV-2.

334
335 We report a high seroprevalence of 49.7% nationally in February 2021, mirroring the
336 upsurge in confirmed COVID-19 cases, hospitalisations and death in Malawi experienced
337 during this period^{3,6}. This is consistent with a study in South African blood donors that
338 reported seroprevalence rates ranging from 31.8% to 62.5% in January 2021³⁷. So far, the
339 epidemic trajectory in Malawi as determined by the national confirmed COVID-19 cases,
340 deaths and hospitalisations has paralleled the epidemic trajectory in South Africa³. This is
341 likely due to shared borders and the resulting frequent human migration between the two
342 countries, specifically in the last 12 months during which there has been an influx of groups
343 of returning residents from South Africa to Malawi. This movement of people coincided with
344 rapid surges in COVID-19 cases in the first and second epidemic waves in Malawi³⁸. These
345 findings support the need for a consolidated and standardised regional public health effort
346 in effectively addressing the COVID-19 pandemic in southern Africa to reduce the risk of
347 further epidemic waves across the region.

348
349 Genomic surveillance data from Malawi and South Africa suggests that this high
350 seroprevalence in the second wave is, at least in part, driven by the emergence of the Beta

351 variant³⁶. In agreement, our neutralisation data showed that sera collected from the second
352 wave (February 2021) was better at neutralising the Beta variant than that from the first
353 wave (June to October 2020), indicating antibody responses driven by infection with the
354 Beta variant rather than the original variant (D614G WT). This is consistent with previous
355 studies showing that homologous convalescent sera retain higher *in vitro* neutralisation
356 potency than heterologous convalescent sera against the infecting virus¹⁵⁻²⁰. It is noteworthy
357 that 35% of the Wave two sera that were positive for antibodies to the SARS-CoV-2 RBD
358 showed no neutralisation against the Beta variant or D614G WT, highlighting a disconnect
359 between qualitative antibody detection and functional activity. This discordance could be
360 due to low anti-RBD antibody titers as they have been shown to be associated with poor *in*
361 *vitro* neutralisation^{19,20}.

362
363 The temporal kinetics of the SARS-CoV-2 seroprevalence in this blood donor serosurvey
364 suggests that the first epidemic wave was largely confined to urban areas. This differs to the
365 second wave, which was not only more rapid in its growth but also in its geographic spread,
366 as shown by the high seroprevalence even in the rural areas. This is consistent with national
367 surveillance reports showing that confirmed COVID-19 cases in the first wave were primarily
368 from the three major cities, Blantyre, Lilongwe and Mzuzu, but in the second wave there
369 was an increase in reported cases in rural areas^{39,40}. Also noteworthy is the earlier
370 seroprevalence peak in Blantyre and Lilongwe, compared to the northern city of Mzuzu.
371 Blantyre and Lilongwe are the largest commercial centres in Malawi with multiple
372 connection to South Africa through international airports and bus stations. Mzuzu is the hub
373 for inter-country trade and migration between Tanzania and Malawi and it is plausible that
374 some of the late epidemic surge in Mzuzu was due to cross border movement of persons
375 between Tanzania and Malawi.

376
377 This study has considerable strengths, including consistent monthly sampling, use of well-
378 validated assays and national geographical representation. There are however some
379 important limitations. First, inherent in using a blood donor sampling frame is that the
380 convenience sampling was not representative of the general population, skewed towards
381 males and individuals aged 18 to 45 years old. In addition, we were unable to evaluate the
382 association between the behaviour of blood donors and risk of acquisition to SARS-CoV-2

383 infection, as this may bias the measured results away from the true population
384 seropositivity. Though random sampling from the larger population would have been ideal,
385 restrictions on movement and gathering make these study designs extremely challenging to
386 implement. Second, in some individuals, SARS-CoV-2 antibodies wane over time to
387 undetectable levels leading to false negatives, especially in those who had asymptomatic
388 COVID-19¹²⁻¹⁴. Therefore, the seroprevalence estimates are likely an underestimate of the
389 cumulative exposure within this sampled population. However, the selection bias and
390 waning of antibody levels is unlikely to substantially alter the temporal trends reported in
391 this study.

392

393 In conclusion, we report a dramatic rise in SARS-CoV-2 seroprevalence from 6.2% in July
394 2020 to 49.7% in February 2021 in healthy blood donors as Malawi experienced the first and
395 second COVID-19 epidemic waves, likely driven initially by the original variant (D614G WT)
396 and then the Beta variant. Based on data showing prior exposure to SARS-CoV-2 augments
397 COVID-19 vaccine responses⁴¹⁻⁴⁴, prioritisation of the first COVID-19 vaccine dose in settings
398 with high seroprevalence could help maximise the benefit of the limited available COVID-19
399 vaccine doses. The dynamics of SARS-CoV-2 exposure will therefore need to be taken into
400 account in the formulation of COVID-19 vaccination policy in Malawi and across the region.

401

402 **Acknowledgements**

403 The authors thank all blood donors whose samples are used in this study, the staff of the
404 Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) and Malawi Blood
405 Transfusion Services (MBTS) for their support and co-operation during the study.

406

407 **Author Contributions**

408 KCJ, TDS, RSH, NF, BM, TM, AM and NK designed the study. KCJ, TDS, TM, GK, AL, NM and
409 PLM supervised the work. JM, CB, AS, FA, ZM, TM, NM, AS and TMG processed all samples
410 and carried out all laboratory-based assays. MYRH, BM and JM carried out data
411 management and statistical analysis. KCJ, TDS, JM, RSH and NF wrote the initial manuscript
412 draft. All authors reviewed and approved the final manuscript.

413

414

415 **Funding**

416 This research was funded by the National Institute for Health Research (NIHR) (16/136/46)
417 using UK aid from the UK Government to support global health research. K.C.J. is supported
418 by an MRC African Research Leader award [MR/T008822/1]. RSH is a NIHR Senior
419 Investigator. The views expressed in this publication are those of the author(s) and not
420 necessarily those of the NIHR or the UK government. P.L.M. is supported by the South
421 African Research Chairs Initiative of the Department of Science and Innovation and the
422 National Research Foundation (Grant No 98341) and the MRC Strategic Health Innovations
423 Program of the SA MRC. A Wellcome Strategic award number 206545/Z/17/Z supports the
424 Malawi-Liverpool-Wellcome Trust Clinical Research Programme. The Malawi Blood
425 Transfusion Service is funded by the Government of Malawi and development partners.

426

427 **Declaration of Interests**

428 The authors declare no competing interests.

429

430 **References**

- 431 1. Coronaviridae Study Group of the International Committee on Taxonomy of V. The
432 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and
433 naming it SARS-CoV-2. *Nat Microbiol* 2020; **5**(4): 536-44.
- 434 2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global
435 health concern. *Lancet* 2020; **395**(10223): 470-3.
- 436 3. JHU. COVID-19 Case Tracker 2020. <https://coronavirus.jhu.edu/map.html>.
- 437 4. Kaye AD, Okeagu CN, Pham AD, et al. Economic impact of COVID-19 pandemic on
438 healthcare facilities and systems: International perspectives. *Best Pract Res Clin Anaesthesiol*
439 2020.
- 440 5. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies
441 for mitigation and suppression in low- and middle-income countries. *Science* 2020.
- 442 6. Morton B, Barnes KG, Anscombe C, et al. Distinct clinical and immunological profiles
443 of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. *Nat Commun* 2021;
444 **12**(1): 3554.

- 445 7. Chibwana M, Jere K, Kamng'ona R, et al. High SARS-CoV-2 seroprevalence in health
446 care workers but relatively low numbers of deaths in urban Malawi [version 2; peer review:
447 2 approved]. *Wellcome Open Research* 2020; **5**(199).
- 448 8. Olayanju O, Bamidele O, Edem F, et al. SARS-CoV-2 Seropositivity in Asymptomatic
449 Frontline Health Workers in Ibadan, Nigeria. *The American journal of tropical medicine and*
450 *hygiene* 2021; **104**(1): 91-4.
- 451 9. Uyoga S, Adetifa IMO, Karanja HK, et al. Seroprevalence of anti-SARS-CoV-2 IgG
452 antibodies in Kenyan blood donors. *Science* 2021; **371**(6524): 79-82.
- 453 10. Peterson I, Bar-Zeev N, Kennedy N, et al. Respiratory Virus-Associated Severe Acute
454 Respiratory Illness and Viral Clustering in Malawian Children in a Setting With a High
455 Prevalence of HIV Infection, Malaria, and Malnutrition. *J Infect Dis* 2016; **214**(11): 1700-11.
- 456 11. Ho A, Mallewa J, Peterson I, et al. Epidemiology of Severe Acute Respiratory Illness
457 and Risk Factors for Influenza Infection and Clinical Severity among Adults in Malawi, 2011-
458 2013. *The American journal of tropical medicine and hygiene* 2018; **99**(3): 772-9.
- 459 12. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody
460 mediated immunity to coronaviruses: kinetics, correlates of protection, and association with
461 severity. *Nat Commun* 2020; **11**(1): 4704.
- 462 13. Anand SP, Prevost J, Nayrac M, et al. Longitudinal analysis of humoral immunity
463 against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom
464 onset. *Cell Rep Med* 2021: 100290.
- 465 14. den Hartog G, Vos ERA, van den Hoogen LL, et al. Persistence of antibodies to SARS-
466 CoV-2 in relation to symptoms in a nationwide prospective study. *Clinical Infectious Diseases*
467 2021.
- 468 15. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and
469 N501Y variants by BNT162b2 vaccine-elicited sera. *Nature Medicine* 2021; **27**(4): 620-1.
- 470 16. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization
471 by South African COVID-19 donor plasma. *Nature Medicine* 2021; **27**(4): 622-5.
- 472 17. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2
473 B.1.1.7 variant by convalescent and vaccine sera. *Cell* 2021; **184**(8): 2201-11.e7.
- 474 18. Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by
475 convalescent plasma. *Nature* 2021; **593**(7857): 142-6.

- 476 19. Moyo-Gwete T, Madzivhandila M, Makhado Z, et al. SARS-CoV-2 501Y.V2 (B.1.351)
477 elicits cross-reactive neutralizing antibodies. *bioRxiv* 2021: 2021.03.06.434193.
- 478 20. Dupont L, Snell LB, Graham C, et al. Antibody longevity and cross-neutralizing activity
479 following SARS-CoV-2 wave 1 and B.1.1.7 infections. *medRxiv* 2021: 2021.06.07.21258351.
- 480 21. Masina L. Judge in Malawi Blocks Government Lockdown, at Least Temporarily.
481 2020. [https://www.voanews.com/covid-19-pandemic/judge-malawi-blocks-government-](https://www.voanews.com/covid-19-pandemic/judge-malawi-blocks-government-lockdown-least-temporarily)
482 [lockdown-least-temporarily](https://www.voanews.com/covid-19-pandemic/judge-malawi-blocks-government-lockdown-least-temporarily).
- 483 22. Star R. Uhuru unlikely to lift curfew, lockdown as Covid-19 cases rise. 2020.
484 [https://www.the-star.co.ke/news/2020-06-05-uhuru-unlikely-to-lift-curfew-lockdown-as-](https://www.the-star.co.ke/news/2020-06-05-uhuru-unlikely-to-lift-curfew-lockdown-as-covid-19-cases-rise/)
485 [covid-19-cases-rise/](https://www.the-star.co.ke/news/2020-06-05-uhuru-unlikely-to-lift-curfew-lockdown-as-covid-19-cases-rise/).
- 486 23. Government SA. President Ramaphosa announces a nationwide lockdown. 2020-03-
487 23 2020. [https://www.sanews.gov.za/south-africa/president-ramaphosa-announces-](https://www.sanews.gov.za/south-africa/president-ramaphosa-announces-nationwide-lockdown)
488 [nationwide-lockdown](https://www.sanews.gov.za/south-africa/president-ramaphosa-announces-nationwide-lockdown).
- 489 24. Mavhunga C. Zimbabwe Begins Lockdown to Fight COVID19. 2020.
490 [https://www.voanews.com/science-health/coronavirus-outbreak/zimbabwe-begins-](https://www.voanews.com/science-health/coronavirus-outbreak/zimbabwe-begins-lockdown-fight-covid19)
491 [lockdown-fight-covid19](https://www.voanews.com/science-health/coronavirus-outbreak/zimbabwe-begins-lockdown-fight-covid19).
- 492 25. Kondowe R. Why a country with no coronavirus cases has declared a national
493 disaster and shut schools. 2020. [https://qz.com/africa/1824465/coronavirus-malawi-with-](https://qz.com/africa/1824465/coronavirus-malawi-with-no-cases-declares-national-disaster/)
494 [no-cases-declares-national-disaster/](https://qz.com/africa/1824465/coronavirus-malawi-with-no-cases-declares-national-disaster/).
- 495 26. Masina L. Malawi President Announces Plans to Reopen Schools in September. 2020.
496 [https://www.voanews.com/covid-19-pandemic/malawi-president-announces-plans-reopen-](https://www.voanews.com/covid-19-pandemic/malawi-president-announces-plans-reopen-schools-september)
497 [schools-september](https://www.voanews.com/covid-19-pandemic/malawi-president-announces-plans-reopen-schools-september).
- 498 27. Cocks T. Malawi to lift Covid-19 international air travel restrictions from September.
499 2020. [https://www.businesslive.co.za/bd/world/africa/2020-08-27-malawi-to-lift-covid-19-](https://www.businesslive.co.za/bd/world/africa/2020-08-27-malawi-to-lift-covid-19-international-air-travel-restrictions-from-september/)
500 [international-air-travel-restrictions-from-september/](https://www.businesslive.co.za/bd/world/africa/2020-08-27-malawi-to-lift-covid-19-international-air-travel-restrictions-from-september/).
- 501 28. Rusakaniko S, Sibanda EN, Mduluza T, et al. SARS-CoV-2 Serological testing in
502 frontline health workers in Zimbabwe. *PLOS Neglected Tropical Diseases* 2021; **15**(3):
503 e0009254.
- 504 29. M'Baya B, Jumbe V, Samuel V, M'Bwana R, Mangani C. Seroprevalence and trends in
505 transfusion transmissible infections among voluntary non-remunerated blood donors at the
506 Malawi Blood Transfusion Service-a time trend study. *Malawi medical journal : the journal*
507 *of Medical Association of Malawi* 2019; **31**(2): 118-25.

- 508 30. NSO. Malawi Population and Housing Census. Zomba: National Statistical Office,
509 Malawi, 2018.
- 510 31. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19 serological
511 assays informs future diagnostics and exposure assessment. *Nature Communications* 2020;
512 **11**(1): 3436.
- 513 32. Wantai. WANTAI SARS-CoV-2 Ab ELISA 2021.
514 <https://www.fda.gov/media/140929/download>.
- 515 33. Wantai. WANTAI SARS-CoV-2 Ab ELISA. 2021.
516 <https://www.bioscience.co.uk/resources/sars-cov-2-ab-elisa-ifu.pdf>.
- 517 34. Henrion MYR. bootComb—an R package to derive confidence intervals for
518 combinations of independent parameter estimates. *International Journal of Epidemiology*
519 2021.
- 520 35. Talebitooti R, Shojaeefard MH, Yarmohammadisatri S. Shape design optimization of
521 cylindrical tank using b-spline curves. *Computers & Fluids* 2015; **109**: 100-12.
- 522 36. Wilkinson E, Giovanetti M, Tegally H, et al. A year of genomic surveillance reveals
523 how the SARS-CoV-2 pandemic unfolded in Africa. *medRxiv* 2021: 2021.05.12.21257080.
- 524 37. Sykes W, Mhlanga L, Swanevelder R, et al. Prevalence of anti-SARS-CoV-2 antibodies
525 among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State
526 provinces of South Africa in January 2021. *Res Sq* 2021: rs.3.rs-233375.
- 527 38. Masina L. 2021. [https://www.voanews.com/covid-19-pandemic/malawi-mandates-](https://www.voanews.com/covid-19-pandemic/malawi-mandates-quarantine-returnees-south-africa)
528 [quarantine-returnees-south-africa](https://www.voanews.com/covid-19-pandemic/malawi-mandates-quarantine-returnees-south-africa).
- 529 39. Government M. COVID-19 - MOH MALAWI. 2021. <https://covid19.health.gov.mw/>.
- 530 40. Ngwira A, Kumwenda F, Munthali ECS, Nkolokosa D. Spatial temporal distribution of
531 COVID-19 risk during the early phase of the pandemic in Malawi. *PeerJ* 2021; **9**: e11003.
- 532 41. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Protection afforded by the
533 BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without
534 prior infection. *medRxiv* 2021: 2021.07.25.21261093.
- 535 42. Havervall S, Marking U, Greilert-Norin N, et al. Antibody Responses After a Single
536 Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-
537 CoV-2. *medRxiv* 2021: 2021.05.08.21256866.

538 43. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in
539 45,965 adults from the general population of the United Kingdom. *Nature Microbiology*
540 2021.

541 44. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in
542 previously SARS-CoV-2-infected individuals. *The Lancet* 2021; **397**(10279): 1057-8.

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570 **Tables**

571

572 **Table 1. Participant Demographics and site characteristics**

573

	Balaka	Blantyre	Lilongwe	Mzuzu	Total
Region	Eastern	Southern	Central	Northern	--
Rural/urban	Rural	Urban	Urban	Urban	--
Pop density (persons/km²)[¶]	205	3334	2455	1516	--
Sampling frame	All locations	Static	Static	Static	--
Gender, % male (N)	74.2% (616)	78.1% (771)	64.1% (606)	84.1% (692)	74.9% (2685)
Age, median (IQR)	20.9 (20.0-25.9)	26.9 (21.9-33.4)	29.8 (22.8-38.2)	25.8 (21.2-33.6)	25.7 (20.8-34.0)
Sample size	830	987	946	823	3586

574

[¶]Source 2018 Malawi Population and Housing Census main report; IQR=interquartile range; Km=kilometre

575

576 **Table 2. SARS-CoV-2 anti-RBD total antibody seroprevalence in blood donors by**

577 **participant characteristics and location**

578

579 This a multivariable logistic regression model with sex, age group, location and time as predictors. B-splines were used to model the effect
580 of time given the non-linear trend in seroprevalence over time.

Variable	Category	Sample size	Seropositive (frequency)	Unadjusted Seroprevalence (%)	Adjusted Seroprevalence (%)	Estimate	SE	z value	p value
Intercept						-14.731	2.213	-6.658	P<0.001
Gender	Female	901	108	12.0	9.5	Ref	Ref	Ref	Ref
	Male	2685	361	13.4	11.0	-0.083	0.133	-0.625	0.532
Age	10 - 19 [§]	420	35	8.3	5.6	Ref	Ref	Ref	Ref
	20 - 29	1844	246	13.3	10.8	0.198	0.181	1.099	0.272
	30 - 39	798	112	14.0	11.6	0.215	0.201	1.067	0.286
	40 - 49	487	72	14.8	12.4	0.322	0.216	1.490	0.136
	50+	37	4	10.8	8.2	-0.577	1.050	-0.549	0.583
Location	Balaka	830	64	7.7	5.5	Ref	Ref	Ref	Ref
	Blantyre	987	160	16.2	14.6	1.005	0.177	5.684	<0.001*
	Lilongwe	946	111	11.7	9.8	0.704	0.187	3.765	<0.001*
	Mzuzu	823	134	16.3	14.6	1.187	0.183	6.496	<0.001*

581

[§] Recruitment limited to blood donors ≥16 years of age

582

* Significant based on p-value < 0.05

583

584

585

586

587

588 **Table 3. Adjusted seroprevalence, stratified by month and site**

589

Yr-month	Balaka % (95% CI)	Blantyre % (95% CI)	Lilongwe % (95% CI)	Mzuzu % (95% CI)	Total % (95% CI)
2020-01	0.0 (0.0, 4.7)	0.0 (0.0, 6.6)	0.0 (0.0, 6.7)	0.0 (0.0, 5.2)	0.0 (0.0, 2.4)
2020-02	0.0 (0.0, 9.5)	0.0 (0.0, 6.6)	0.0 (0.0, 7.9)	0.0 (0.0, 6.4)	0.0 (0.0, 2.8)
2020-03	0.0 (0.0, 6.8)	1.5 (0.0, 11.1)	0.0 (0.0, 6.7)	0.0 (0.0, 7.1)	0.0 (0.0, 2.8)
2020-04	0.0 (0.0, 7.0)	0.0 (0.0, 7.1)	0.0 (0.0, 6.8)	0.0 (0.0, 8.6)	0.0 (0.0, 2.8)
2020-05	0.0 (0.0, 9.5)	0.0 (0.0, 6.1)	0.2 (0.0, 12.5)	1.3 (0.0, 10.4)	0.0 (0.0, 3.9)
2020-06	0.0 (0.0, 6.2)	0.0 (0.0, 9.6)	0.0 (0.0, 5.4)	0.0 (0.0, 8.8)	0.0 (0.0, 2.7)
2020-07	0.0 (0.0, 6.2)	15.9 (2.9, 31.2)	7.3 (0.0, 16.4)	6.6 (0.0, 17.6)	6.2 (0.5, 11.4)
2020-08	0.0 (0.0, 6.7)	14.7 (3.3, 27.6)	13.1 (2.2, 25.6)	13.7 (0.0, 40.9)	8.4 (1.7, 14.4)
2020-09	0.0 (0.0, 4.7)	14.6 (4.8, 25.0)	7.2 (0.1, 14.5)	18.2 (6.6, 31.3)	9.4 (3.0, 14.9)
2020-10	0.0 (0.0, 10.8)	16.7 (7.0, 26.8)	8.1 (0.2, 16.5)	24.8 (14.8, 35.2)	15.7 (8.9, 22.0)
2020-11	0.6 (0.0, 8.7)	15.6 (6.0, 25.9)	13.9 (5.4, 22.6)	6.8 (0.0, 14.7)	10.4 (4.0, 15.8)
2020-12	1.9 (0.0, 12.0)	11.0 (2.5, 19.8)	6.0 (0.0, 16.5)	13.4 (3.1, 25.0)	9.1 (2.7, 14.9)
2021-01	23.9 (9.4, 40.2)	23.2 (13.2, 33.7)	18.8 (8.8, 29.7)	34.7 (19.9, 50.7)	24.0 (16.7, 31.2)
2021-02	37.5 (26.7, 49.0)	54.8 (42.4, 67.5)	54.5 (39.8, 70.4)	57.5 (44.4, 72.1)	49.7 (42.3, 58.8)

590

591

592

593

594

595

596

597

598

599

600

601

602

603


604

605

606

607

608



619
620
621 **Figure 1. Overall SARS-CoV-2 adjusted seroprevalence over time superimposed on Malawi**
622 **national PCR-confirmed COVID-19 cases.** Black dots (together with 95% CI) are estimated
623 seroprevalence at each timepoint (month), adjusted for assay sensitivity and specificity. The
624 histograms represent confirmed national COVID-19 cases per month, including
625 asymptomatic and symptomatic cases. Case frequency reported above histograms (June
626 2020 and February 2021) indicates reported cases at the peak of 1st and 2nd wave,
627 respectively. Vertical dotted line defines transition from 2020 to 2021. SARS-CoV-2 = Severe
628 acute respiratory syndrome coronavirus 2, COVID-19 = Coronavirus disease 2019, Ab+ =
629 Positive for detection of anti- SARS-CoV-2 receptor binding domain (RBD) antibody.

630
631
632
633
634
635
636
637
638
639
640

641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672




Figure 2. Flexible seroprevalence models. The model fits provide a smoothed estimate of the seroprevalence over time (January 2020 to February 2021) for each location: Blantyre, Lilongwe, Balaka, and Mzuzu. The orange line is the line of best fit for the empirical data, using a smooth generalised additive model, along with light-orange shading indicating 95% CI. Black dots (together with 95% CI) are estimated seroprevalence at each timepoint (month), adjusted for assay sensitivity and specificity. Grey dots (a top and bottom of figures) show the individual-level data, which are either positive (1) or negative (0) for detection of anti-SARS-CoV-2 receptor binding domain (RBD) antibody.

673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703





Figure 3. Seroprevalence bubble plot for overall seroprevalence at three snapshots in time. The size of the bubble is proportional to the prevalence of samples positive for anti-SARS-CoV-2 receptor binding domain (RBD) antibody within each location.



704

705

706 **Figure 4. SARS-CoV-2 neutralisation of D614G WT and Beta variant using sera from the**

707 **first and second epidemic waves.** Anti-RBD seropositive sera from the SARS-CoV-2 epidemic

708 Wave 1 and 2 were subjected to a SARS-CoV-2 pseudovirus neutralisation assay. a)

709 Correlation of SARS-CoV-2 antibody neutralisation potency against D614G WT and Beta

710 variant. b) Magnitude of neutralisation potency of Wave 1 (n=9) and Wave 2 (n=17) sera

711 against D614G WT and Beta variant. Sera with a ratio of >1 are classified as Beta variant-

712 induced antibodies, <1 as D614G WT-induced antibodies and 1 as undefined. c) Proportion

713 of Wave 1 and Wave 2 sera with relatively higher neutralisation potency against D614G WT

714 and Beta variant. The threshold of detection for the neutralization assay is ID₅₀>20. RBD,

715 Receptor Binding Domain.

716